

**ORIGINAL****Comparison of endogenous hypothalamic and serum OT levels between young and middle-aged perimenopausal female rats**

Rie Masaki, Yuri Yamamoto, Kou Tamura, Hidenori Aoki, Hiroki Noguchi, Asuka Takeda, Saki Minato, Risa Tanano, Erika Yamanaka, Takaaki Maeda, Tatsuo Sugimoto, Hikari Sasada, Hiroaki Inui, Tomohiro Kagawa, Atsuko Yoshida, Ayuka Mineda, Riyo Kinouchi, Kanako Yoshida, Takashi Kaji, and Takeshi Iwasa

*Department of Obstetrics and Gynecology, Graduate School of Biomedical Sciences, Tokushima University, Tokushima, Japan*

**Abstract :** Oxytocin (OT) regulates food intake and body weight, particularly in obese individuals. Decreases in the effects of OT have recently been implicated in metabolic disturbances, and the administration of estradiol (E2) increased serum OT levels. Although weight gain is frequently observed in perimenopausal women, endogenous OT levels remain unclear. Therefore, we herein compared endogenous levels of hypothalamic and serum OT between young and middle-aged perimenopausal female rats and examined the relationship between serum estrogen and leptin levels. Body weight and visceral and subcutaneous fat weights were higher in middle-aged rats. Although no significant differences were observed in serum OT and E2 levels, serum leptin levels and hypothalamic mRNA levels of OT and the OT receptor (OTR) were significantly higher in middle-aged rats than in young rats. Serum OT levels did not correlate with hypothalamic OT mRNA levels or serum E2 levels. E2 maintains serum OT levels in perimenopausal rats, and other factors may elevate hypothalamic OT/OTR mRNA levels. Increases in body and fat weights in perimenopausal rats may be attributed to factors other than OT. Therefore, the administration of OT alone may not be sufficient to prevent metabolic disorders induced by the perimenopausal status. *J. Med. Invest.* 71:246-250, August, 2024

**Keywords :** Oxytocin, obesity, perimenopause, estrogen

**INTRODUCTION**

Oxytocin (OT) is a neuropeptide that is synthesized in the magnocellular neurons of the paraventricular nucleus and the supraoptic nucleus of the hypothalamus (1, 2). It induces contractions of the uterus during labor and milk ejection during lactation in females (3). Recent studies demonstrated that OT regulated metabolism, feeding behavior, and body weight in both sexes (4, 5). For example, OT receptor (OTR)-deficient mice developed late-onset obesity and increases in abdominal fat (6), and injections of an OT antagonist into the third ventricle of mice increased their food intake (7). In contrast, when exogenous OT was centrally or peripherally administered, appetite and/or body weight decreased (8, 9), lipolysis was promoted, and fat mass was reduced (5, 10). Furthermore, these effects of OT were more prominent in individuals with obesity.

The postmenopausal state is associated with weight gain, obesity, and several metabolic disorders, such as diabetes mellitus, hyperlipidemia, hypertension, and cardiovascular disease (11-14). Since ovariectomized (OVX) female rodents show similar metabolic phenotypes to menopausal women, they are often used in research as a menopausal model (15). We previously reported reductions in the hypothalamic gene expression of OT and OTR and serum levels of OT in OVX female rats and demonstrated that the administration of exogenous OT induced decreases in food intake, body weight gain, and fat mass (16). These findings implicate a decrease in the effects of OT in OVX-induced metabolic disturbances and indicate the potential of OT as a

candidate anti-obesity drug for postmenopausal women. In another study, we found that supplementation with estradiol (E2) restored hypothalamic and serum OT levels in OVX rats, indicating a relationship between estrogen deficiency and decreases in the effects of OT under postmenopausal conditions (17). Moreover, we showed that food intake in ovary-intact old rats, a model of perimenopausal women, was reduced following the administration of OT, whereas body weight remained unchanged, suggesting no significant differences in the effects of exogenous OT between perimenopausal and postmenopausal women (18). In contrast, in OVX rats, central and peripheral OT levels and the relationship between OT and estrogen levels in perimenopausal rats remain unclear. In addition, the administration of exogenous leptin, an anorectic factor, activated hypothalamic OT (19). Based on these findings, the present study investigated the endogenous levels of hypothalamic and serum OT in perimenopausal female rats and examined the relationship between serum estrogen and leptin levels.

**MATERIALS AND METHODS***Animals*

Seven 10-week-old (young) and seven 12-month-old (middle-aged) Sprague-Dawley female rats (Charles River, Kanagawa, Japan) were housed in a temperature-controlled room (24°C) with a 12-h light/dark cycle. It was previously confirmed that 12-month-old rats may be comparable to the perimenopausal status (i.e., irregular estrous cyclicity or acyclicity). All procedures performed in animal experiments followed the ethical standards of the Institutional Animal Care and Use Committee of the University of Tokushima. Food intake was measured for four weeks. After the induction of anesthesia with sevoflurane, rats were euthanized by decapitation. The brain, blood, and visceral fat (300–400 mm<sup>2</sup>) were removed and visceral and subcutaneous

Received for publication January 11, 2024 ; accepted April 15, 2024.

Address correspondence and reprint requests to Yuri Yamamoto, Department of Obstetrics and Gynecology, Institute of Biomedical Sciences, Tokushima University Graduate School, 3-18-15 Kuramoto-cho, Tokushima 770-8503, Japan and Fax : +81-88-631-2630.

fat weights were evaluated. The visceral fat was dissected parametric, perirenal and mesenteric deposits, and subcutaneous fat were dissected inguinal deposits. The brain sections were dissected out via an anterior coronal cut at the posterior border of the mammillary bodies, parasagittal cuts along the hypothalamic fissures, and a dorsal cut 2.5 mm from the ventral surface. Serum and tissues were stored at  $-20$  and  $-80^{\circ}\text{C}$ , respectively.

#### Hormone assay

The measurement of serum OT levels was outsourced to a commercial laboratory (ASKA Pharmaceutical Medical Inc., Co., Ltd., Fujisawa city, Kanagawa, Japan) where assessments were performed using a chemiluminescent enzyme immunoassay according to a previously described method (20-22). The measurement of serum E2 levels were also outsourced to a commercial laboratory (SRL, Tokyo, Japan) where a chemiluminescence immunoassay kit with a detection limit of 10 pg/mL and coefficient of variation  $<7\%$  was used for evaluations. A radioimmunoassay kit (multi-species leptin RIA kit, Linco Research Inc., MO, USA) with a sensitivity of 1.0 ng/ml and inter- and intra-assay coefficients of variation of 3.2 and 7.8%, respectively, was used to measure serum leptin levels.

#### Quantitative real-time polymerase chain reaction (PCR)

Following the dissection of whole hypothalamic explants from frozen brains using a previously described method (20), total RNA was isolated using a TRIzol® reagent kit (Invitrogen Co., Carlsbad, CA, USA) and RNeasy® mini kit (Qiagen GmbH, Hilden, Germany). Total RNA was also isolated from visceral fat using the same method. The SuperScript III First-Strand Synthesis System for real-time PCR (Invitrogen Co.) was employed to synthesize cDNA with oligo (deoxythymidine) primers at  $50^{\circ}\text{C}$ . The StepOnePlus™ real-time PCR system (PE Applied Biosystems, Foster city, CA, USA) and FAST SYBR® green were used for PCR. Hypothalamic mRNA levels of OT and OTR and visceral fat mRNA levels of OTR were quantified and then normalized to that to GAPDH or the rRNA level of 18S. Each gene was subjected to a dissociation curve analysis after PCR, with each amplicon generating a single peak. Table 1 shows the relevant primer sequences, product sizes, and annealing temperatures. PCR was performed under the following conditions: initial denaturation and enzyme activation at  $95^{\circ}\text{C}$  for 20 s, followed by 45 cycles of denaturation at  $95^{\circ}\text{C}$  for 3 s, and annealing and extension for 30 s.

#### Statistical analysis

All results are shown as means  $\pm$  SD. The Student's unpaired *t*-test was performed to examine the significance of differences. Correlation analyses were conducted using Pearson's correlation,

whereas appropriate. Differences were considered to be significant at  $P < 0.05$ .

## RESULTS

Body weights were significantly higher in middle-aged rats than in young rats. However, cumulative food intake over four weeks was similar (Figure 1). Visceral and subcutaneous fat weights were significantly higher in middle-aged rats than in young rats, indicating that middle-aged rats were more likely to be obese (Figure 1). Serum E2 and OT levels did not significantly differ between middle-aged and young rats, whereas serum leptin levels were significantly higher in middle-aged rats than in young rats (Figure 2). Hypothalamic OT and OTR mRNA levels were significantly higher in middle-aged rats than in young rats, whereas visceral fat OTR mRNA levels were similar. Serum OT levels did not correlate with hypothalamic OT mRNA levels (Figure 2). Serum leptin levels correlated with serum OT levels and hypothalamic OT mRNA levels, whereas serum E2 levels did not (Figure 3, 4). According to these results, in middle-aged rats, serum E2 and OT levels did not decrease and hypothalamic OT and OTR mRNA levels were higher than in young rats.

## DISCUSSION

Peri- and postmenopausal women are at an increased risk of developing obesity and associated metabolic disorders. However, there are currently no established medical interventions for these conditions. OT was recently shown to regulate metabolism, feeding behavior, and body weight gain in animals and humans, and the direct and indirect involvement of OT in lipid metabolism in adipose tissue has been demonstrated (4, 5). In our previous study, we found reductions in serum and hypothalamic OT levels in OVX female rats, a model of postmenopausal women, and also that the administration of exogenous OT decreased body weight, food intake, and fat weights (16, 17). In addition, serum OT levels were lower in postmenopausal women than in premenopausal women (23). Therefore, a decrease in the effects of OT appears to play a role in the development of obesity in postmenopausal cases, and OT has potential as a drug candidate for these conditions. Furthermore, we reported reductions in food intake, but not body or fat weight, following the administration of exogenous OT to middle-aged female rats, a model of perimenopausal women (18), indicating the weaker effects of OT in perimenopausal cases than in postmenopausal cases. However, we did not examine the conditions of endogenous OT in middle-aged

Table 1.

| Primer           | Sequence                        | Annealing T ( $^{\circ}\text{C}$ ) |
|------------------|---------------------------------|------------------------------------|
| OT forward       | GAA CAC CAA CGC CAT GGC CTG CCC | 62                                 |
| OT reverse       | TCG GTG CGG CAG CCA TCC GGG CTA |                                    |
| OTR forward      | CGA TTG CTG GGC GGT CTT         | 67                                 |
| OTR reverse      | CCG CCG CTG CCG TCT TGA         |                                    |
| GAPDH forward    | ATG GCA CAG TCA AGG CTG AGA     | 64                                 |
| GAPDH reverse    | CGC TCC TG GAA GAT GGT GAT      |                                    |
| 18S rRNA forward | GAC GGA CCA GAG CGA AAG C       | 64                                 |
| 18S rRNA reverse | AAC CTC CGA CTT TCG TTC TTG A   |                                    |




Figure 1. Body weight, cumulative food intake, and visceral and subcutaneous fat weights in young (Young) and middle-aged (Middle) rats. Data are expressed as means + SD values. \*  $P < 0.05$ , \*\*  $P < 0.01$ .




Figure 2. Serum levels of estradiol (E2), leptin, and oxytocin (OT), hypothalamic mRNA levels of OT and OT receptor (OTR), and visceral fat mRNA levels of OTR in young (Young) and middle-aged (Middle) rats. Data are expressed as means + SD values. \*\*  $P < 0.01$ .





Figure 3. Correlation between serum oxytocin (OT) and hypothalamic OT mRNA levels.



**Figure 4.** Correlation between serum estradiol (E2) and oxytocin (OT) levels, serum E2 and hypothalamic OT mRNA levels, serum leptin and OT levels, and serum leptin and hypothalamic OT mRNA levels.

perimenopausal rats in our previous study, but measured serum and hypothalamic OT levels in rats in the present study. The results obtained showed that serum OT levels were similar in middle-aged rats and young rats, while hypothalamic OT and OTR mRNA levels were higher in middle-aged rats than in young rats. Therefore, in contrast to OVX rats, the effects of hypothalamic OT may be enhanced in middle-aged rats. Nevertheless, body and fat weights were higher in middle-aged rats than in young rats. We speculate that increases in body and fat weights in middle-aged perimenopausal rats were caused by factors other than OT, and that elevated hypothalamic OT and OTR mRNA levels may be a counter-regulation to attenuate body weight gain and prevent obesity. The present results also revealed that hypothalamic OT mRNA levels did not correlate with serum OT levels and, thus, central and peripheral OT may be independently regulated. Previous studies reported the peripheral effects of OT (i.e., OT directly promoted lipolysis in adipose tissue through OTR). However, OTR mRNA levels in visceral fat did not significantly differ between middle-aged and young rats in the present study. Therefore, changes in the direct effects of OT may not be related to the accumulation of fat in middle-aged rats (4).

We previously reported reductions in the hypothalamic mRNA levels of OT and OTR and serum levels of OT in OVX rats, and these decreases were restored by supplementation with E2 (17). Furthermore, the administration of E2 increased serum OT levels in postmenopausal women, particularly those with obesity (24), and the co-administration of OT antagonists reduced the anorectic effects of the exogenous E2 supplementation in OVX rats (25). A correlation was also observed between hypothalamic OTR mRNA levels and serum E2 concentrations in aging female rats (26). Therefore, the effects of endogenous OT and/or OTR appear to be regulated by E2, while the anorectic effects of E2 may be mediated, at least partly, by endogenous OT. The results

obtained herein revealed no significant differences in serum E2 levels between middle-aged and young rats and serum E2 levels did not correlate with serum OT levels or hypothalamic OT mRNA levels. Therefore, E2 maintains serum OT and hypothalamic OT/OTR mRNA levels, and other factors may increase hypothalamic OT/OTR mRNA levels in middle-aged perimenopausal rats. As described above, the effects of exogenous OT on body weight did not significantly differ between middle-aged rats and OVX rats in our previous study. Since the endogenous effects of OT are already enhanced under perimenopausal conditions, any additive effects by exogenous OT may be limited. The administration of exogenous leptin, an anorectic factor, activates hypothalamic OT (19). In the present study, serum leptin levels were higher in middle-aged rats than in young rats, and serum leptin levels correlated with serum OT levels and hypothalamic OT mRNA levels. Therefore, endogenous leptin may be associated with endogenous OT levels, at least in the rats examined in this study.

In summary, endogenous serum OT and E2 levels were not lower in perimenopausal rats than in younger rats, and in contrast to hypothalamic and serum OT levels, E2 levels did not correlate with leptin levels. Moreover, body and fat weight gain in perimenopausal cases may be induced by factors other than OT. Therefore, the administration of OT alone may not be sufficient to prevent metabolic disorders induced by the perimenopausal status.

## CONFLICTS OF INTEREST

No conflicts of interest exist.

## ACKNOWLEDGMENT

None

## REFERENCES

1. du Vigneaud V, Ressler C, Trippett S : The sequence of amino acids in oxytocin, with a proposal for the structure of oxytocin. *J Biol Chem* 205(2) : 949-957, 1953
2. Brownstein MJ, Russell JT, Gainer H : Synthesis, transport, and release of posterior pituitary hormones. *Science* 207 : 373-378, 1980
3. Dale HH : On some physiological actions of ergot. *J Physiol (Lond)* 34 : 163-206, 1906
4. McCormack SE, Blevins JE, Lawson EA : Metabolic effects of oxytocin. *Endocr. Rev.* 41 : 121-145, 2020
5. Altirriba J, Poher A-L, Caillon A, Arsenijevic D, Veyrat-Durebex C, Lyautey J, Dulloo A, Rohner-Jeanrenaud F : Divergent effects of oxytocin treatment of obese diabetic mice on adiposity and diabetes. *Endocrinology* 155 : 4189-4201, 2014
6. Takayanagi Y, Kasahara Y, Onaka T, Takahashi N, Kawada T, Nishimori K : Oxytocin receptor deficient mice developed late-onset obesity. *Neuroreport* 19 : 951-955, 2008
7. Zhang G, Bai H, Zhang H, Dean C, Wu Q, Li J, Guariglias, Meng Q, Cai D : Neuropeptide exocytosis involving synaptotagmin-4 and oxytocin in hypothalamic programming of body weight and energy balance. *Neuron* 69 : 523-535, 2011
8. Maejima Y, Iwasaki Y, Yamahara Y, Kodaira M, Sedbazar U, Yada T : Peripheral oxytocin treatment ameliorates obesity by reducing food intake and visceral fat mass. *Aging (Albany NY)* 3 : 1169-1177, 2011
9. Arletti R, Benelli A, Bertolini A : Influence of oxytocin on feeding behavior in the rat. *Peptides* 10 : 89-93, 1989
10. Zhang G, Cai D : Circadian intervention of obesity development via resting-stage feeding manipulation or oxytocin treatment. *Am J Physiol Endocrinol. Metab.* 301 : E1004-E1012, 2011
11. Lovejoy JC, Champagne CM, Jonge LD, Xie H, Smith SR : Increased visceral fat and decreased expenditure during the menopausal transition. *Int J Obes (Lond)* 32(6) : 949-958, 2008
12. Knight MG, Anekwe C, Washington K, Akam EY, Wang E, Stanford FC : Weight Regulation in Menopause. *Menopause* 28(8) : 960-965, 2022
13. Stachowiak G, Pertynski T, Pertynska-Marczewska M : Metabolic disorders in menopause. *Prz. Menopauzalny* 14 : 59-64, 2015
14. Jeong HG, Park H : Metabolic disorders in Menopause. *Metabolites*. 12(10) : 954, 2022
15. Iwasa T, Matsuzaki T, Yano K, Irahara M : The effects of ovariectomy and lifelong high-fat diet consumption on body weight, appetite, and lifespan in female rats. *Horm Behav.* 97 : 25-30, 2018
16. Iwasa T, Matsuzaki T, Mayila Y, Yanagihara R, Yamamoto Y, Kawakita T, Kuwahara A, Irahara M : Oxytocin treatment reduced food intake and body fat and ameliorated obesity in ovariectomized female rats. *Neuropeptides*. 75 : 49-57, 2019
17. Tokui T, Kawakita T, Yanagihara R, Kamada S, Minato S, Takeda A, Imaizumi J, Yamamoto Y, Yoshida K, Kato T, Minoru I, Iwasa T : Effects of gonadal status and the estrogen milieu on hypothalamic oxytocin gene expression and serum oxytocin levels in female rats. *Horm Behav.* 133, 2021
18. Erdenebayar O, Kato T, Kawakita T, Kasai K, Kadota Y, Yoshida K, Iwasa T, Irahara M : Effects of peripheral oxytocin administration on body weight, food intake, adipocytes, and biochemical parameters in peri- and postmenopausal female rats. *Endocr J* 28 : 68(1) : 7-16, 2021
19. Blevins JE, Schwartz MW, Baskin DG : Evidence that paraventricular nucleus oxytocin neurons link hypothalamic leptin action to caudal brain stem nuclei controlling meal size. *Am. J. Phys. Regul Integr* 287(1) : R87-96, 2004
20. Yamamoto S, Noguchi H, Takeda A, Arakaki R, Uchishiba M, Imaizumi J, Minato S, Kamada S, Kagawa T, Yoshida A, Kawakita T, Yamamoto Y, Yoshida K, Kon M, Shinohara N, Iwasa T : Changes in Endogenous Oxytocin Levels and the Effects of Exogenous Oxytocin Administration on Body Weight Changes and Food Intake in Polycystic Ovary Syndrome Model Rats. *Int J Mol Sci.* 23(15) : 8207, 2022
21. Yamamoto S, Arakaki R, Noguchi H, Takeda A, Uchishiba M, Kamada S, Mineda A, Kon M, Kawakita T, Kinouchi R, Yamamoto Y, Yoshida K, Shinohara N, Iwasa T : New discoveries on the interaction between testosterone and oxytocin in male rats - Testosterone-mediated effects of oxytocin in the prevention of obesity. *Physiol Behav.* 266, 2023
22. Imaizumi J, Kamada S, Taniguchi M, Sugimoto T, Maeda T, Arakaki R, Yamamoto S, Shirakawa A, Mineda A, Yoshida A, Iwasa T, Kaji T : Developmental Changes in Hypothalamic and Serum Oxytocin Levels in Prenatally Normally Nourished and Undernourished Rats. *15(12) : 2768, 2023*
23. Maestrini S, Mele C, Mai S, Vietti R, Blasio AD, Castello L, Surico D, Aimaretti G, Scacchi M, Marzullo P : Plasma oxytocin concentration in pre- and postmenopausal women : its relationship with obesity body composition and metabolic variables. *Obes Acts* 11(5) : 429-439, 2018
24. Bossmar T, Forsling M, Akerlund M : Circulating oxytocin and vasopressin is influenced by ovarian steroid replacement in women. *Acta Obstet Gynecol Scand* 74(7) : 544-548, 1995
25. Sloan DK, Spencer DS, Curtis KS : Estrogen effects on oxytocinergic pathways that regulate food intake. *Horm Behav* 105 : 128-137, 2018
26. Garcia AN, Depena CK, Yin W, Gore AC : Testing the critical window of estradiol replacement on gene expression of vasopressin, oxytocin, and their receptors, in the hypothalamus of aging female rats. *Mol Cell Endocrinol.* 419 : 102-112, 2016